|
pubmed:otherAbstract |
PIP: On a random basis, 19 patients with metastatic and recurrent ovarian carcinoma received 100, 200, or 400 mg daily of medroxyprogesterone acetate orally. All patients had previously failed to respond to cytotoxic therapy. None of the 5 patients receiving 100 mg/day had an objective response. 1 of the 9 patients receiving 200 mg/day had an objective response for 4 months and 2 had their disease remain static for 4 and 5 months. None of the 5 patients who received 400 mg/day had an objective response but 1 had her disease remain static for 7 months. All epithelial ovarian cell types were included in the study. During drug therapy no change was found in hemoglobin levels, leukocyte counts, platelet counts, serum levels of creatinine, bilirubin, alkaline phosphatase, glutamic oxaloacetic transaminase, fasting blood sugar, or urine. Data from these 19 patients indicate that this drug, as used, had no significant benefit.
|
